About ContraMed

Leadership Team

A diverse and experienced team of professionals with proven track records for identifying and bringing to market innovative medical device and pharmaceutical solutions.

Bob H. Katz  – Chief Executive Officer, President, Director

Bob Katz is a successful start-up executive with experience bringing a variety of medical devices and technologies to market. He joined ContraMed in 2010 and has been responsible for the on-going design, development and clinical evaluation of the company’s lead products, as well as general corporate management, intellectual property development and fundraising.

Bob started his career in engineering and research capacities for Cordis Corporation, developing implantable pulse generators, lead systems and later coronary vascular devices as Manager, Advanced Devices Research. He led product and clinical development efforts as Vice President, Research & Development at Symphonix Devices, an implantable hearing device start-up that went public. He was later President & COO of Revivant Corporation, which developed and commercialized AutoPulse, an automated Cardiac Resuscitation System. Revivant was acquired by ZOLL Medical. He was subsequently President of early stage start-up Aptus Endosystems, which developed an endovascular stapling system and was later acquired by Medtronic.

Bob earned a BSEE and BA from Rutgers University and a MS in Biomedical Engineering from Boston University. He also holds an MBA from Southeastern University. He is a listed inventor on over a two dozen patents and applications and is co-author on numerous clinical papers and presentations.

Michael Tal, MD – Chief Technology Officer, Director

Michael Tal is the Principal at Access Medical Ventures in Tel Aviv, Israel.  He has been an associate Professor of Radiology at the Yale University School of Medicine since 1999.  Michael is an interventional radiologist with expertise in minimally invasive procedures.  He graduated from Hadassah Medical School in Jerusalem, Israel in 1995, and completed medical training at MCP Hahnemann University in Philadelphia and Yale University in 2000.  Michael completed his MBA at Yale business school in 2007.

Dr. Tal co-founded ContraMed in 2006 and currently acts as the company’s Chief Technology Officer and Director. He has co-founded several medical device companies and brought several medical devices to market.  He works closely with medical device industry companies in the U.S.

Kevin Peters, PhD – Vice President, Clinical Affairs

Kevin Peters is an experienced clinical manager with expertise in both the medical device and pharmaceutical sectors.  He joined ContraMed in 2015.  Kevin was previously Senior Director of Clinical Affairs for KONA Medical, managing multiple global renal denervation device trials.  Before KONA Medical, he was Director of Clinical Affairs for Pathway Medical a medical device start-up in the cardiovascular space, and was Clinical Operations Director for Cell Therapeutics where he managed a major Phase III multinational lung cancer drug therapy study.  Kevin has substantial experience in clinical trials management, both from a sponsor and CRO perspective.

Dr. Peters has an undergraduate degree in Human Biology from the University of San Francisco, San Francisco, CA and Masters/Ph.D. in Clinical Pharmacology and Clinical Research, also from the University of San Francisco.

Sandra Matsumoto, PhD – Vice President, Regulatory Affairs

Sandra Matsumoto joined ContraMed in February 2017 and brings over 16 years of experience in the biotechnology and pharmaceutical sectors. Prior to joining ContraMed, Sandra was the Vice President of Global Regulatory Affairs for Evofem Biosciences, Inc., defining and executing effective regulatory strategies to optimize global development and commercial opportunities for non-hormonal contraception and preventative treatments for bacterial vaginosis and sexually transmitted infections. She was also responsible for implementing a commercial regulatory function and led regulatory oversight of global partnering and licensing activities. Her experience covers several therapeutic areas beyond women’s health including endocrine and metabolic disorders, obesity, cardiovascular and liver diseases for drugs, biologics, medical devices and combination products. Prior to Evofem, Sandra was the Senior Director of Global Regulatory Affairs for Vital Therapies, Inc., where she led registration activities for an orphan-designated cell therapy for acute liver failure. Her prior positions involved increasing levels of responsibility in the areas of regulatory affairs, clinical development and discovery research at several companies including Shire Regenerative Medicine, Amylin Pharmaceuticals, Illumina and Sequenom.

Dr. Matsumoto earned her PhD in Pharmacology and Toxicology from the University of Utah, her Master of Science in Biology degree from California State University, Northridge and her Bachelor of Science degree in Biology from UCLA. She holds active RAC certifications for the US and EU.